Cold Spring Harbor molecular case studies, volume 4, issue 6, pages a003137

Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma

Jenny J. Ko 1
Jasleen K. Grewal 2
Tony T.C. Ng 3
Jean-Michel Lavoie 4
My Linh Thibodeau 5
Yaoqing Shen 2
Andrew J. Mungall 2
Greg Taylor 2
Kasmintan A. Schrader 6
Steve M. R. Jones 2
Christian Kollmannsberger 4
Janessa Laskin 4
M. Marra 2
Show full list: 13 authors
1
 
Systemic Therapy, BC Cancer - Abbotsford, Abbotsford, British Columbia V2S 0C2, Canada.
2
 
Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
3
 
Department of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada.
4
 
Systemic Therapy, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
6
 
Hereditary Cancer Program, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
Publication typeJournal Article
Publication date2018-11-16
scimago Q2
SJR0.801
CiteScore3.2
Impact factor1.8
ISSN23732873, 23732865
General Medicine
Abstract

Thyroid-like follicular renal cell carcinoma (TLFRCC) is a rare cancer with few reports of metastatic disease. Little is known regarding genomic characteristics and therapeutic targets. We present the clinical, pathologic, genomic, and transcriptomic analyses of a case of a 27-yr-old male with TLFRCC who presented initially with bone metastases of unknown primary. Genomic DNA from peripheral blood and metastatic tumor samples were sequenced. A transcriptome of 280 million sequence reads was generated from the same tumor sample. Tumor somatic expression profiles were analyzed to detect aberrant expression. Genomic and transcriptomic data sets were integrated to reveal dysregulation in pathways and identify potential therapeutic targets. Integrative genomic analysis with The Cancer Genome Atlas (TCGA) data set revealed the following outliers in gene expression profiles: CDK6 (81st percentile), MYC (99th percentile), AR (100th percentile), PDGFRA and PDGFRB (99th and 100th percentiles, respectively), and MAP2K2 (86th percentile). The patient received first-line sunitinib to target PDGFRA and PDGFRB and had stable disease for >6 mo, followed by nivolumab upon progression. To the authors’ knowledge, this is the first reported case of comprehensive somatic genomic analyses in a patient with metastatic TLFRCC. Somatic analyses provided molecular confirmation of the primary site of cancer and potential therapeutic strategies in a rare disease with little evidence of efficacy on systemic therapy.

Found 
Found 

Top-30

Journals

1
2
3
1
2
3

Publishers

1
2
3
4
1
2
3
4
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Share
Cite this
GOST | RIS | BibTex | MLA
Found error?